NeuroOne Medical (NMTC) Fundamental Analysis: Revenue, Earnings & Valuation

8.84 / 10

Outperform

Fundamental metrics score 8.8/10, rated Outperform. Asset‑MV and Profit‑MV are strong (group 1‑4), while Revenue‑MV and Net‑profit‑to‑Total‑Profit lag (negative returns). Cash‑MV, ROA and margin ratios sit in top quartiles, indicating robust balance‑sheet health.

Analysis Checks(8/10)

Revenue-MV

Value-0.11

Score0/3

Weight-24.10%

1M Return-4.18%

ROA (%)

Value-44.63

Score3/3

Weight13.25%

1M Return1.81%

Net cash flow from operating activities / Operating revenue (%)

Value-31.19

Score2/3

Weight10.54%

1M Return1.48%

Profit-MV

Value0.66

Score2/3

Weight22.76%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-44.63

Score3/3

Weight13.25%

1M Return1.81%

EBIT / Total operating revenue (%)

Value-35.96

Score3/3

Weight11.33%

1M Return1.53%

Asset-MV

Value-0.55

Score3/3

Weight34.57%

1M Return4.62%

Net profit / Total operating revenue (%)

Value-39.63

Score2/3

Weight9.02%

1M Return1.26%

Cash-MV

Value0.02

Score3/3

Weight22.70%

1M Return2.92%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight-13.32%

1M Return-2.39%

Is NMTC undervalued or overvalued?

NMTC scores 8.84/10 on fundamentals and holds a Discounted valuation at present. Backed by its -21.34% ROE, -119.46% net margin, -5.90 P/E ratio, 6.30 P/B ratio, and 30.77% earnings growth, these metrics solidify its Outperform investment rating.